Varför tar Sam Altman Metformin
GeoGazet Underrättelser· Uppdaterad 5 okt 2026· 1 min läsning· 489 visningar
There is no credible evidence that Sam Altman, OpenAI's CEO since 2019, takes metformin.
This claim lacks substantiation in public records, health disclosures, or verified reporting.
Altman's health information remains private.
Läs hela rapportenVisa mindre
Varför tar Sam Altman Metformin
Public Focus on AI Development
Altman's documented activities center on OpenAI's product roadmap. Recent initiatives include OpenAI Dots, his unveiled ChatGPT AI personal agent, alongside the 2026 DevDay announcements. His tracked signals show 94 connections to Artificial Intelligence developments.
Speculation Without Basis
Health rumors about prominent figures often circulate online without verification. Without direct statements from Altman or credible medical sources, claims about his medications should be treated as unsubstantiated speculation rather than fact.
Följ Altman live.Varje uppdatering publiceras på vår Telegram.
Gå med på TelegramLäsarrecensioner
Inga recensioner än. Var den första som delar din åsikt.